Radiation dose in CT-guided microwave liver tumor ablation
, 2, 3, 1, 1, 1
Abstract
Introduction.Ablation is one of most important methods of liver tumor treatment. However, radiation is one of disadvantages of CT-guided procedures including ablation. The purpose of this study is to assess the factors that have impact on radiation doses during CT-guided microwave liver tumor ablation.
Material and methods.Radiation doses of CT-guided liver tumor ablations were collected in 127 patients. They were then compared in terms of number of lesions, lesion size and depth, use of additional localization needles and hydrodissection as well as tumor location.
Results.The median radiation doses of ablations of multiple tumors (2348 mGy*cm) were significantly higher (p = 0.03) than those of single tumors (1784 mGy*cm). No statistically significant differences were noted when other factors (lesion size, depth, location, use of localization needles and hydrodissection) were taken into consideration.
Conclusions.The number of lesions is the most important factor in terms of expected radiation doses in CT-guided microwave liver tumor ablations.
Keywords: microwave ablationradiation doseCT-guided ablation
References
- Benson AlB, D'Angelica MI, Abbott DE, et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(5): 541–565.
- NCCN. Hepatobiliary cancers (Hepatocelluar) v. 2.2021. NCCN. 2021.
- Baère Tde. Computed Tomography Imaging for Tumor Ablation. Tumor Ablation. 2005: 104–120.
- Brenner DJ, Elliston CD, Hall EJ, et al. Estimated Risks of Radiation. Am Roentgen Ray Soc. 2001; 176: 289–96.
- Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology. 2009; 251(1): 175–184.
- Coakley FV, Gould R, Yeh BM, et al. CT radiation dose: what can you do right now in your practice? AJR Am J Roentgenol. 2011; 196(3): 619–625.
- The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007; 37(2-4): 1–332.
- Wang X, Sofocleous CT, Erinjeri JP, et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol. 2013; 36(1): 166–175.
- Hu EY, Levesque VM, Bay CP, et al. Liver Tumor Ablation Procedure Duration and Estimated Patient Radiation Dose: Comparing Positron Emission Tomography/CT and CT Guidance. J Vasc Interv Radiol. 2020; 31(7): 1052–1059.
- McCarthy CJ, Kilcoyne A, Li X, et al. Radiation Dose and Risk Estimates of CT-Guided Percutaneous Liver Ablations and Factors Associated with Dose Reduction. Cardiovasc Intervent Radiol. 2018; 41(12): 1935–1942.
- Crocetti L, de Baére T, Pereira PL, et al. CIRSE Standards of Practice on Thermal Ablation of Liver Tumours. Cardiovasc Intervent Radiol. 2020; 43(7): 951–962.
- Sarti M, Brehmer WP, Gay SB. Low-dose techniques in CT-guided interventions. Radiographics. 2012; 32(4): 1109–19; discussion 1119.
- Rosiak G, Lusakowska A, Milczarek K, et al. Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis. Neuroradiology. 2021; 63(4): 539–545.
- Bosch de Basea M, Moriña D, Figuerola J, et al. Subtle excess in lifetime cancer risk related to CT scanning in Spanish young people. Environ Int. 2018; 120: 1–10.
- Liu Y, Li S, Wan X, et al. Efficacy and safety of thermal ablation in patients with liver metastases. Eur J Gastroenterol Hepatol. 2013; 25(4): 442–446.
- Fang Y, Chen W, Liang X, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014; 29(1): 193–200.
- Ruers T, Van Coevorden F, Punt CJA, et al. European Organisation for Research and Treatment of Cancer (EORTC), Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017; 109(9).